Latest News & Features
Americas
The outcome of Apple’s smartwatch dispute at the Federal Circuit may provide important guidance for meeting the US’ threshold domestic industry requirement, write Nathan Mammen and Cole Tipton of Snell & Wilmer. 30 July 2025
Americas
Texas pharmacy accused of mass-producing unapproved tirzepatide drugs | Lilly claimed pharmacy falsely marketed copycat versions of Mounjaro and Zepbound as safe and effective | It warned of “conducting a mass testing experiment on consumers without safety controls or informed consent”. 29 July 2025
Americas
Swiss pharma giant files patent infringement lawsuit to stop Teva’s generic Mekinist launch in US | Follows European Patent Office revocation of key patent after Teva proved lack of inventive step. 28 July 2025
Americas
Jennifer Che of Eagle IP explores key IP challenges in China and offers practical strategies to address them, covering topics such as AI, patent linkage and export controls in this LSPN session. 28 July 2025
Americas
US State Department has said it is engaging with Chinese officials to resolve situation | Federal employee failed to disclose he worked for US government, according to a report. 25 July 2025
Europe
Court delivers default judgment dismissing EOFlow’s patent revocation claim | Dispute escalates following EOFlow’s refusal to post security amid financial concerns | Following detailed analysis, it upholds infringement claims ordering sales ban across 17 countries. 24 July 2025
Europe
Design and colour combination deemed ‘too common’ in the pharma sector for protection | Court says trademarks must be distinctive across the EU, not just individual countries. 24 July 2025
Europe
Court of Appeal backs Astellas in UK patent fight over prostate cancer drug | Generics’ challenge fails as judges warn on expert evidence and hindsight bias | Court urges caution when instructing expert witnesses in obviousness cases. 23 July 2025
Americas
$56M awarded to AbbVie unit in Delaware patent fight over Botox treatment | US Botox sales reportedly grew to over $4.4 billion last year, while trade secrets lawsuit against rival continues. 22 July 2025
Americas
Judge said it was unjustified to allow pharma giant’s exclusivity to continue indefinitely | Loss of monopoly over $7.8bn drug set to have marked revenue impact on the company. 22 July 2025